We are live on ! Find out more
RLYB icon

Rallybio
RLYB

Fund managers haven’t disclosed any holdings of RLYB yet.

RLYB Hedge Fund Activity: Q1 2026 in Review

38 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q1 2026, worth a combined $41.9M — up 102% from $20.7M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of RLYB and 13 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 7 added.

The largest buyer was Fidelity Investments, adding an estimated $3.98M. The largest seller was Johnson & Johnson, cutting an estimated $2.06M.

  • 38 institutional investors held Rallybio (RLYB) as of Q1 2026, down from 46 in Q4 2025.
  • Funds reported $41.9M of Rallybio stock for Q1 2026, up 102% quarter-over-quarter.
  • 13 funds opened new Rallybio positions in Q1 2026 and 20 closed out, a net change of -7 holders.
  • The largest Rallybio buyer in Q1 2026 was Fidelity Investments, an estimated $3.98M added.
  • The largest Rallybio seller in Q1 2026 was Johnson & Johnson, an estimated $2.06M sold.

Based on aggregated 13F filings for Q1 2026.